[1]牛四明,罗欢欢.新辅助化学治疗联合手术治疗局部晚期乳腺癌疗效观察[J].新乡医学院学报,2017,34(5):429-431.[doi:10.7683/xxyxyxb.2017.05.022]
　NIU Si-ming,LUO Huan-huan.Effect of neoadjuvant chemotherapy combined with surgery in the treatment of locally advanced breast cancer[J].Journal of Xinxiang Medical University,2017,34(5):429-431.[doi:10.7683/xxyxyxb.2017.05.022]
点击复制

新辅助化学治疗联合手术治疗局部晚期乳腺癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年5
页码:
429-431
栏目:
临床研究
出版日期:
2017-05-05

文章信息/Info

Title:
Effect of neoadjuvant chemotherapy combined with surgery in the treatment of locally advanced breast cancer
作者:
牛四明1; 罗欢欢2
（1.周口市中医院普外科，河南　周口　466000；2.新乡医学院组织学与胚胎学教研室，河南　新乡　453003）
Author(s):
NIU Si-ming1; LUO Huan-huan2
（1.Department of General Surgery，Zhoukou Hospital of Traditional Chinese Medicine，Zhoukou 466000，Henan Province，China；2.Department of Histology and Embryology，Xinxiang Medical University，Xinxiang 453003，Henan Province，China）
关键词:
新辅助化学治疗; 乳腺癌; 外科手术
Keywords:
neoadjuvant chemotherapy; breast cancer; surgery
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2017.05.022
文献标志码:
A
摘要:
目的　探讨新辅助化学治疗（NAC）联合手术治疗局部晚期乳腺癌（LABC）的临床效果。方法　选择2009年1月至2011年12月周口市中医院收治的Ⅱb、Ⅲa和Ⅲb期LABC患者60例，根据治疗方法分为观察组和对照组，每组30例。观察组患者术前给予NAC 2～3个周期，化学治疗结束后2周内行手术治疗；对照组患者在排除禁忌证后即行手术治疗；术后2组患者均给予常规化学治疗。对2组患者的临床疗效、生存率、局部复发及肿瘤转移情况进行比较。结果　观察组和对照组患者治疗总有效率分别为76.67%（23/30）和46.67%（14/30），观察组患者治疗总有效率显著高于对照组（χ2=5.711，P<0.05）。观察组患者术后转移率和局部复发率分别为16.67%（5/30）和13.33%（4/30），对照组患者术后转移率和局部复发率分别为33.33%（10/30）和23.33%（7/30），观察组患者术后转移率和复发率均显著低于对照组（χ2=4.297、4.236，P<0.05）。观察组患者术后1、3、5 a生存率分别为83.33%（25/30）、63.33%（19/30）和46.67%（14/30），对照组患者术后1、3、5 a生存率分别为66.67%（20/30）、40.00%（12/30）和20.00%（6/30），观察组患者术后1、3、5 a生存率均显著高于对照组（χ2=4.126、4.353、4.800，P<0.05）。结论　NAC能显著提高LABC患者的临床治疗效果和生存率，降低肿瘤复发率和转移率。
Abstract:
Objective　To investigate the clinical effect of neoadjuvant chemotherapy（NAC）combined with surgery in the treatment of locally advanced breast cancer（LABC）.Methods　Sixty patients with LABC of stage Ⅱb，Ⅲa and Ⅲb were selected From January 2009 to December 2011 in Zhoukou Hospital of Traditional Chinese Medicine；the patients were divided into observation group and control group according to the treatment method，30 patients in each group.The patients in the observation group were treated with NAC for 2-3 cycles before operation，and the patients were treated with surgery within two weeks after chemotherapy.The patients in the control group were treated with surgery after the exclusion of contraindications.The patients in the two groups were treated with routine chemotherapy after operation.The clinical effect，survival rate，local recurrence and tumor metastasis were compared between the two groups.Results　The total effective rate in the observation group and the control group was 76.67%（23/30）and 46.67%（14/30）respectively，the total effective rate in the observation group was significantly higher than that in the control group（χ2=5.711，P<0.05）.The postoperative metastasis rate and local recurrence rate in the observation group were 16.67%（5/30）and 13.33%（4/30）respectively，and they were 33.33%（10/30）and 23.33%（7/30）in the control group respectively，the postoperative metastasis rate and local recurrence rate in the observation group were significantly lower than those in the control group（χ2=4.297，4.236；P<0.05）.The 1-，3- and 5-year survival rates in the observation group were 83.33%（25/30），63.33%（19/30）and 46.67%（14/30）respectively；and they were 66.67%（20/30），40.00%（12/30）and 20.00%（6/30）in the control group respectively；the 1-，3- and 5-year survival rates in the observation group were significantly higher than those in the control group（χ2=4.126，4.353，4.800；P<0.05）.Conclusion　NAC can significantly improve the clinical effect and survival rate，and reduce the recurrence rate and metastasis rate of LABC patients.

参考文献/References:

［1］　武春梅，王圣应.新辅助化疗在乳腺癌保乳手术中的应用价值探讨［J］.中华内分泌外科杂志，2012，6（5）：338-340.
［2］　付彤，张湜，张海鹏，等.新辅助化疗后乳腺癌患者前哨淋巴结活检的可行性评价［J］.吉林大学学报（医学版），2014，40（4）：866-869.
［3］　张斌.乳腺癌的新辅助化疗［J］.中华肿瘤杂志，2013，25（3）：209-210.
［4］　李树玲.乳腺肿瘤学［M］.北京：科学技术文献出版社，2000：432-433.
［5］　HAYWARD J L，CARBONE P P，HEUSON J C，et al.Assessment of response to therapy in advanced breast cancer［J］.Br J Cancer，1977，39（3）：1289-1294.
［6］　陈盛，陈灿铭.乳腺癌的新辅助化疗［J］.中国癌症杂志，2012，22（9）：714-718.
［7］　HULIKAL N，GAJJALA S R，KALAWAT T C，et al.Utility of fluorodeoxyglucose positron emission tomography/computed tomography（FDG PET/CT）in the initial staging and response assessment of locally advanced breast cancer patients receiving neoadjuvant chemotherapy［J］.Indian J Surg Oncol，2015，6（4）：330-336.
［8］　MOHAMMADIANPANAH M，ASHOURI Y，HOSEINI S，et al.The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer：a randomized phase Ⅲ clinical trial［J］.Breast Cancer Res Treat，2012，132（3）：853-861.
［9］　唐峰，吴蕴.新辅助化疗乳腺癌病理标本的处理对策及报告规范［J］.中华病理学杂志，2013，38（1）：8-12.
［10］　杨绍英，刘朝荣，张志刚，等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达［J］.新乡医学院学报，2017，34（2）：125-128.
［11］　刘雁冰，杨涛，张朝蓬，等.乳腺癌新辅助化疗后原发肿瘤退缩模式预测列线图的建立［J］.吉林大学学报（医学版），2014，40（6）：1319-1324，1338.
［12］　EI HAGE CHEHADE H，HEADON H，KASEM A，et al.Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-observation node-positive breast cancer：an update for clinical practice［J］.Anticancer Res，2016，36（4）：1461-1471.
［13］　钟广俊，周茂松.局部晚期乳腺癌新辅助化疗后的保乳手术治疗［J］.江苏医药，2011，37（20）：2466-2467.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王　乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]薛会朝,王　雷,李　建,等.乳腺癌干细胞及其分化细胞中雌激素受体、孕激素受体和人类表皮生长因子受体2的表达[J].新乡医学院学报,2017,34(5):361.[doi:10.7683/xxyxyxb.2017.05.004]
　XUE Hui-chao,WANG Lei,LI Jian,et al.Expression of estrogen receptor，progesterone receptor and human epidermal growth factor receptor 2 in breast cancer stem cells and their differentiated cells[J].Journal of Xinxiang Medical University,2017,34(5):361.[doi:10.7683/xxyxyxb.2017.05.004]
[11]张　婷,刘起鹏,郭婉莹,等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报,2020,37(11):1075.[doi:10.7683/xxyxyxb.2020.11.016]
　ZHANG Ting,LIU Qipeng,GUO Wanying,et al.Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis[J].Journal of Xinxiang Medical University,2020,37(5):1075.[doi:10.7683/xxyxyxb.2020.11.016]
[12]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
　YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor，progestin recetor，Ki-67 antigen，and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(5):125.[doi:10.7683/xxyxyxb.2017.02.012]

更新日期/Last Update: 2017-05-05